Advanced Enzyme Q1 Review - Inline; Revenue Growth Was Driven Mainly By Human Nutrition Segment: Nirmal Bang

Nirmal Bang Report

Overall for FY24, Advanced Enzyme Technologies Ltd.'s management has guided for ~15% revenue growth and improvement in margin compared to FY23.

While in a normal environment, the management’s aspiration is to clock ~15-20% revenue compound annual growth rate with Ebitda margin of ~40%, it is still away from normalcy, in our view.

Overall, we are building in revenue/Ebitda/adjusted profit after tax CAGR of 17%/31%/24% over FY23-FY25E.

We maintain 'Accumulate' with a revised target price of Rs 320 (earlier Rs 300) post earnings revision.

We continue to value Advanced Enzyme at 20 times price-to-earning i.e. a significant discount to Novozymes’ (global leader in industrial enzymes) valuation primarily on account of lower-than-expected growth delivery and rising competition.

A meaningful acquisition(s) and/or strengthening of the leadership team could be some of the re-rating triggers, in our view.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.